ReviewFrontiers in allergy2025
Key role of thymic stromal lymphopoietin as a molecular target for biologic treatment of severe asthma.
Review in Frontiers in allergy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Vascular remodeling in asthma: from mechanisms to precision medicine.Current opinion in allergy and clinical immunology · 2026Review
- Epithelial alarmins TSLP, IL-33, and IL-25 in asthma pathogenesis: mechanistic roles and therapeutic implications.Molecular biology reports · 2026Review
- Biologic Use in Type 2 versus Non-Type 2 Asthma: Similarities, Differences, and Challenges.Journal of inflammation research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thymic stromal lymphopoietin (TSLP) is an alarmin mainly released by airway epithelial cells injured by many environmental noxious agents such as aeroallergens, respiratory viruses, bacteria, airborne pollutants and cigarette smoking. Airway expression levels of TSLP are related to both asthma severity and the extent of bronchial obstruction occurring in asthmatic patients. The pivotal pathogenic role played by TSLP in asthma is due to its capability of acting as an upstream driver of multiple cellular and molecular proinflammatory pathways, responsible for the development and persistence of both type 2 (T2-high) and T2-low asthma. Tezepelumab is a fully human monoclonal antibody which specifically binds to TSLP, thus impeding its interaction with the TSLP receptor complex expressed by immune/inflammatory and resident cells of the airways. By virtue of this very effective mechanism of action, tezepelumab prevents disease exacerbations and improves lung function. These positive outcomes have been verified by randomized clinical trials, as well as by preliminary real-life studies. The aim of this narrative review is to provide an overview of the pathogenic involvement of TSLP in asthma, followed by an updated discussion focused on the therapeutic effects induced by tezepelumab in severe asthmatic patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.